Tuberculosis and COVID-19 co-infection in Serbia: Pandemic challenge in a low-burden country.
COVID-19
Serbia
co-infection
pandemic
tuberculosis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
06
2022
accepted:
17
10
2022
entrez:
5
12
2022
pubmed:
6
12
2022
medline:
6
12
2022
Statut:
epublish
Résumé
COVID-19 and tuberculosis (TB) represent global threats to the public health system. The impact of COVID-19 on TB results in a reduction in the number of notified TB cases, delayed diagnosis and treatment, and increased case fatality and mortality rates. The aim of the study was to analyze the TB/COVID-19 co-infected cohort in Serbia as a low-burden country and compare it to the global TB/COVID-19 cohort. A retrospective analysis was done on 53 TB and COVID-19 co-infected patients treated in COVID hospital "Batajnica" in Belgrade and Special Hospital for Pulmonary Diseases "Ozren" Sokobanja in the period from 6 March 2020 to 1 April 2022. A comparative analysis with the global cohort published recently was also performed. TB/COVID-19 cohort in Serbia included significantly fewer migrants and diabetes cases, but more cases with chronic respiratory diseases compared to the global. Descriptive analysis of TB cases in the Serbian TB/COVID-19 cohort showed fewer cases diagnosed with sputum smear and Gene Xpert/HAIN, fewer EPTB and mono-resistant cases, and more cases diagnosed with solid culture, unilateral pulmonary infiltrate (with bilateral cavity lesions), and bilateral pulmonary infiltrate (no cavities) compared to TB/COVID-19 cases worldwide. Nasal congestion and fever were more common COVID-19 symptoms in the global cohort. Radiology was more commonly used for the diagnosis of COVID-19 in Serbia. Typical bilateral ground opacities were less common among Serbian patients. Serbian patients spent fewer days in the hospital and achieved a higher PCR conversion rate and TB treatment success rate. The Serbian TB/COVID-19 cohort achieved a higher treatment success rate compared to the global cohort. Encouraging vaccination against SARS-CoV-2 for people with a current or past TB disease, as well as rapid diagnosis and targeted treatment of TB in highly specialized pulmonology institutions, presents key points to avoid excessive morbidity and mortality.
Identifiants
pubmed: 36465947
doi: 10.3389/fmed.2022.971008
pmc: PMC9709136
doi:
Types de publication
Journal Article
Langues
eng
Pagination
971008Informations de copyright
Copyright © 2022 Adzic-Vukicevic, Stosic, Antonijevic, Jevtic, Radovanovic-Spurnic and Velickovic.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2020 Aug 11;11:1991
pubmed: 32903476
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Int J Tuberc Lung Dis. 2016 Aug;20(8):1010-4
pubmed: 27393532
EClinicalMedicine. 2020 Oct 24;28:100603
pubmed: 33134905
Int J Mol Sci. 2021 Apr 06;22(7):
pubmed: 33917321
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34764184
Eur Respir J. 2020 Jul 9;56(1):
pubmed: 32457198
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Int Immunopharmacol. 2021 Nov;100:108121
pubmed: 34492533
Lancet Respir Med. 2022 Jun;10(6):603-622
pubmed: 35338841
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Infection. 2021 Oct;49(5):1061-1064
pubmed: 33454928
Afr J Thorac Crit Care Med. 2020 Apr 21;26(2):
pubmed: 34240023
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Antibiotics (Basel). 2021 Mar 08;10(3):
pubmed: 33800406
Vaccines (Basel). 2022 May 25;10(6):
pubmed: 35746446
Vaccines (Basel). 2021 Oct 22;9(11):
pubmed: 34835161
J Infect Dev Ctries. 2022 Mar 31;16(3):478-483
pubmed: 35404853
AJR Am J Roentgenol. 2020 May;214(5):1072-1077
pubmed: 32125873
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Pulmonology. 2020 Jul - Aug;26(4):233-240
pubmed: 32411943
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Clin Transl Sci. 2020 Sep;13(5):842-844
pubmed: 32402130
Front Med (Lausanne). 2021 Aug 24;8:657006
pubmed: 34504847
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32513784
Lancet Respir Med. 2020 Sep;8(9):914-924
pubmed: 32717211
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33945513